(ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system (RAS) modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200. The company said that of those 167 subjects enrolled across 43 clinical sites, 106 have been recruited in sites across the UK, 60 in the Netherlands and 1 in Italy. DMX-200 has regulatory approval in both the UK and the Netherlands and is available at sites for administration to patients randomised to the DMX-200 treatment arm. In the REMAP-CAP approved ACE2 RAS study domain, participants who meet platform entry criteria will be randomised to receive one RAS blockade treatment arm or a control: